Elevance Health, Inc. (ELV) — BATS 46/100 — 2026-07-15

Listen to the earnings call audio for free on StockAnalysis

Summary based on Elevance Health, Inc. earnings call on 2026-07-15

BotFlo AI Transformation Score for $ELV: 46 (46/100)

Sector AI Transformation Score for $ELV: 17 (17/50)

Presentation

(1/5) Q2 results beat and raised 2026 EPS guidance
• 📈 Second quarter results exceeded outlook on favorable benefit expense, disciplined execution, and enterprise cost-management actions.
• 💰 Full-year 2026 adjusted diluted EPS guidance was raised to at least $27, with confidence in at least 12% adjusted EPS growth in 2027 off the 2026 baseline.
• 🤖 Progress is described as broad-based across Medicare Advantage, commercial and ACA, Carelon, and increasingly meaningful AI-enabled capabilities.

(2/5) Capability investments for cost, experience, and providers
• ⏱️ Medical cost trend detection is being accelerated so months of work can be compressed into days with faster targeted interventions.
• 📱 Sydney Health Concierge and proactive engagement use data, digital tools, and care teams to simplify navigation and close gaps in care.
• 🔗 Health OS collaborates earlier with providers to reduce avoidable denials, documentation requests, and administrative friction while CareBridge targets mid-teens medical savings.

(3/5) Medicaid discipline, market exits, and trough-year framing
• 📉 Medicaid remains dynamic; Q2 supports the full-year framework and the operating margin outlook is unchanged and prudent.
• 📅 Management continues to view 2026 as the trough year for Medicaid margin with improvement over time from rate alignment and care-management maturation.
• ⚠️ Elevance reached a mutual agreement to exit DC Medicaid and expects additional Medicaid market exits over the next 12 to 18 months where returns are not sustainable.

(4/5) Medicare Advantage, ACA, commercial, and Carelon performance
• 📊 Medicare Advantage actions on plan design, D-SNP/HMO mix, claims, and care management support a path to at least 2% operating margin this year.
• 🏥 Individual ACA is developing as priced with encouraging retention, while commercial demand is strong for integrated medical-pharmacy, advocacy, behavioral, and digital capabilities.
• 💡 Carelon behavioral programs delivered about 10% average cost savings and are positioned as a durable enterprise growth driver as capabilities scale.

(5/5) CFO financial detail, investments, and outlook
• 💵 Adjusted diluted EPS was $7.45 in Q2, with operating revenue of $49.8 billion and 44.9 million medical members.
• 🔧 A $0.80 per-share below-the-line benefit will fund one-time second-half investments in medical cost management, member engagement, provider connectivity, and Carelon capabilities.
• 📈 Full-year adjusted EPS guidance moves to at least $27, cash flow to at least $6 billion, with at least $26 as the 2027 growth baseline for 12% EPS growth.

Q&A

(1/15) Q&A: Medicaid second-half margin trajectory and market-exit sizing
• 📈 Q2 was broad-based and ahead of outlook, supporting raised guidance to at least $27 while keeping a prudent second-half view.
• 🧾 The original full-year Medicaid framework remains intact on stronger rates, aligned membership/acuity, and maturing cost actions in a still-dynamic environment.
• 📅 Second-half Medicaid margin is expected to improve from Q2 on favorable July 1 rate activity and continued cost-pressure execution.

(2/15) Q&A: Medicaid exit magnitude and acuity versus conservative assumptions
• 🔍 Q2 Medicaid cost trend developed in line with the expected framework, with elevated but identifiable drivers in behavioral health, ED, outpatient surgery, and specialty pharmacy.
• 👥 Management is not seeing a new step-wise acuity reset; membership and acuity remain aligned, with incremental pressure from utilization among remaining members.
• 🧭 July rates were modestly favorable, but the outlook still assumes no material back-half trend improvement and keeps a prudent full-year margin.

(3/15) Q&A: ACA risk adjustment favorability and 2026 posture
• ✅ Final 2025 risk adjustment results were quite favorable versus prior estimate, reinforcing confidence in estimation and reserving.
• ⚠️ That favorability is not being extrapolated into 2026 because the ACA market, member mix, and Bronze shift are still developing.
• 📊 Much of the 2025 favorability is being reestablished in the 2026 risk adjustment accrual as intentional prudence.

(4/15) Q&A: Trend results versus guidance for Medicaid, ACA, and MA
• 📉 In Medicaid, persistent pressure is increasingly utilization-driven among members who remain, while the post-PHE acuity-reset dynamic is moderating.
• 📈 ACA trend was in line to slightly favorable in Q2 on volume and timing dynamics, without changing the full-year earnings profile.
• 🧩 Favorability reflected Bronze orientation and better early membership rather than a structural earnings-profile change.

(5/15) Q&A: Sequential seasonal favorability and whether first-half upside reverses
• 💰 About $0.50 of operating outperformance in the quarter was split roughly equally between Medicare Advantage and individual ACA.
• 📊 ACA favorability reflected pronounced Bronze seasonality similar to Q1 plus favorable final 2025 risk adjustment, most of which was reestablished.
• 🛡️ Full-year outlook treatment is prudence for the second half rather than an expected mechanical reversal signal.

(6/15) Q&A: 2027 ACA/MA bidding posture and Medicaid exit criteria
• 🎯 ACA 2027 posture remains consistent with 2026: disciplined market-specific pricing for sustainable margin amid cost trend and evolving morbidity, with continued Bronze emphasis.
• 🏥 Medicaid stays core, but participation requires strategic and financial fit; DC exit is mutual and additional exits are planned where economics are not sustainable.
• 🔗 Commitment is stronger where duals alignment, Carelon strategy, and a sustainable operating framework are present.

(7/15) Q&A: One-time investments, operating leverage, and 2027 returns
• 🔧 Investment costs are one-time and nonrecurring into 2027 and target durable capabilities in medical cost, member experience, provider connectivity, claims accuracy, and efficiency.
• 🤖 Medical cost management investments include analytics and AI-enabled tools to identify pressures earlier and implement clinical, payment-integrity, and network interventions.
• 📱 Sydney Health touches about 22 million members, Health OS aims at fewer documentation requests and 80% real-time prior authorization, and Carelon solutions such as CareBridge are being accelerated.

(8/15) Q&A: Why Medicaid margins are unchanged if rates are better
• 📅 Second-half Medicaid trend outlook stays consistent with first-half experience and is described as quite prudent.
• 💵 July rate activity was favorable toward the upper end of mid-single digits, but full-year benefit is moderated by timing and book mix.
• 🧭 Market exits reflect long-term sustainability, dual footprint, and portfolio fit, not only near-term 2026–2027 rate prints.

(9/15) Q&A: Medicaid trough versus OBBBA, work requirements, and macro headwinds
• 🧩 Management frames upcoming Medicaid regulatory items as manageable within the existing framework of rate alignment, actions, and portfolio discipline.
• 👥 For 2027, some incremental acuity pressure from community engagement and verification is expected, but not a broad reset comparable to the post-PHE unwind.
• 📋 Work-requirement impacts are viewed as phased, state-specific, and limited mainly to expansion/waiver members representing roughly 20% of the book.

(10/15) Q&A: First-half utilization shape and whether $0.80 investments reverse next year
• 📊 Q2 Medicaid cost trend was not an acceleration beyond expectations and was consistent with Q1 after adjusting for flu and prior-year development.
• 💵 About $0.75 of EPS for targeted investment spending was already in the ongoing run rate, including AI adoption and workforce enablement.
• 🔧 The additional roughly $0.80 of below-the-line favorability funds one-time 2026 accelerated investments and is not recurring in 2027; the 12% growth jump-off is the $26 baseline.

(11/15) Q&A: Outpatient surgery pressure mix and catch-up risk
• 🏥 Outpatient surgery is not a universal trend driver, though it matters in certain lines of business.
• 📈 Medicaid outpatient surgery trend is more utilization-driven, while local group is more unit-cost/mix-driven.
• 📉 Medicare and individual ACA show moderately lower surgery trends, with ACA per-member utilization contemplated in pricing for higher morbidity.

(12/15) Q&A: Reserve posture prudence entering Q2
• 🛡️ Management remains confident that reserving levels and posture are consistent and prudent versus membership, inventory, experience, and prior practice.
• 📅 Days in claims payable ended at 45.4 days, up 2.9 days year over year.
• ✅ The company feels good about reserving posture as of quarter-end.

(13/15) Q&A: Medicare Advantage utilization trends, bids, and Stars
• 🎯 2027 MA bids followed the same disciplined multi-year strategy, with a prudent trend view because medical cost trend is still seen as outpacing program funding.
• 📊 2026 portfolio actions are performing as expected and keep MA on track for at least 2% margin, informing 2027 bids.
• 🤖 Stars remains a core multiyear priority with investments including AI-powered personalized member engagement, omnichannel outreach, rewards, interoperability, and gap-closure programs.

(14/15) Q&A: Commercial enrollment, pricing versus trend, and integrated model runway
• 🏢 Fee-based/self-funded commercial, spanning local and national accounts, is performing very well with rising persistency and sales conversion.
• 🔁 National accounts had a record 2026 and a similarly large 2027 pipeline, including win-backs of customers that had left for other payers.
• 💵 Pricing is set to the forward view of medical cost trend with discipline to support sustainable margins over time.

(15/15) Q&A: Early 2027 outlook versus long-term growth algorithm
• 📈 Confidence in 2027 rests on breadth and durability of the earnings base rather than any single line of business or recovery assumption.
• 🧩 Base case expects Medicaid improvement as rates catch experience and actions mature, plus continued MA discipline, strong commercial sales, and consistent ACA positioning.
• 💰 Disciplined capital deployment remains an EPS growth contributor, supporting a broad-based path to at least 12% adjusted EPS growth in 2027.